Welcome to our dedicated page for Stoke Therapeutics SEC filings (Ticker: STOK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Finding the real story behind Stoke Therapeutics’ next-generation RNA medicines isn’t easy—each 10-K details complex TANGO science, shifting R&D spend and cash runway nuances that can sway valuations overnight. If you have ever searched for Stoke Therapeutics SEC filings explained simply and come away with more questions than answers, this page is built for you.
Stock Titan’s AI sifts through every newly posted record on EDGAR, from a Stoke Therapeutics quarterly earnings report 10-Q filing to a sudden Stoke Therapeutics 8-K material events explained, then delivers plain-English summaries and red-flag alerts. Need to track Stoke Therapeutics insider trading Form 4 transactions or want Stoke Therapeutics Form 4 insider transactions real-time? Our platform surfaces those moves seconds after executives file, so you never miss a signal. Key takeaways from the Stoke Therapeutics annual report 10-K simplified—pipeline milestones, IP updates, liquidity outlook—are highlighted automatically, while footnotes are linked to clear definitions for faster context.
Investors typically drill into SEC documents for three reasons:
- Gauge R&D progress and upcoming FDA milestones via 10-Q trends and 8-K trial readouts.
- Monitor capital needs, dilution risk and Stoke Therapeutics proxy statement executive compensation structures.
- Spot conviction signals in Stoke Therapeutics executive stock transactions Form 4.
Whether you want a quick Stoke Therapeutics earnings report filing analysis or are understanding Stoke Therapeutics SEC documents with AI for deeper due diligence, Stock Titan offers real-time updates, expert annotations and machine-generated bullet-point briefs—all without wading through hundreds of biotech-specific pages.
Stoke Therapeutics reported financial results for the quarter ended June 30, 2025 and provided business updates, including new data from ongoing open label extension (OLE) studies of zorevunersen extending out to three years and the initiation of a Phase 1 clinical study of STK-002 in patients with Autosomal Dominant Optic Atrophy (ADOA).
The company furnished a press release and an investor presentation as Exhibits 99.1 and 99.2, with the presentation including certain key findings from an analysis of the OLE studies; the company states these materials are furnished, not filed, and are not incorporated by reference into other filings.
Stoke Therapeutics and Biogen issued a joint press release announcing that the first patient has been dosed in the global Phase 3 EMPEROR study of zorevunersen for the treatment of Dravet syndrome. The company furnished that press release as Exhibit 99.1 to this Form 8-K and also included the cover page interactive XBRL file.
The filing states the furnished information, including Exhibit 99.1, is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated. The report is executed on behalf of Stoke by Chief Financial Officer Thomas E. Leggett.
Schedule 13G/A filing by FMR LLC (and Abigail P. Johnson) reports beneficial ownership in Stoke Therapeutics, Inc. (CUSIP 86150R107). The filing states 7,412,982 shares beneficially owned, representing 13.6% of the class as of the 06/30/2025 event date. Signatures dated 08/05/2025 certify the securities are held in the ordinary course of business and not for the purpose of changing or influencing control.
- Issuer: STOKE THERAPEUTICS INC; principal office 45 WIGGINS AVENUE, BEDFORD, MA 01730.
- Reporting persons: FMR LLC (entity) and Abigail P. Johnson (individual).
- Voting/dispositive power: FMR reports 7,405,833 sole voting power and 7,412,982 sole dispositive power; no shared power reported.
FAQ
What is the current stock price of Stoke Therapeutics (STOK)?
What is the market cap of Stoke Therapeutics (STOK)?
